Ono Pharmaceutical Co (4528.T) Stock Price
Ono Pharmaceutical Co Price
Revenue has compounded at 7.0% per year over the past 19 years to 515.79 B JPY. Earnings per share have grown at 3.7% per year over the last 19 years. Ono Pharmaceutical Co's net margin stands at 13.5%, down from 22.3% several years earlier. Ono Pharmaceutical Co currently offers a dividend yield of about 4.79%. The payout ratio is around 46% of earnings. The dividend has grown at 9.0% per year over the past 19 years. Analysts set a median price target of 1,989.00 JPY, implying 20.6% below the current price. Of 20 analysts, 1 rate the stock a buy — an overall Hold consensus.
Ono Pharmaceutical Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Ono Pharmaceutical Co business model & stock analysis
Frequently asked questions about Ono Pharmaceutical Co
The business model of Ono Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Ono focuses on the development of prescription drugs in various therapeutic areas, including oncology, immunology, and central nervous system disorders. Ono Pharmaceuticals' business model emphasizes a strong commitment to scientific excellence and collaboration with research institutions and other pharmaceutical companies. By continually investing in cutting-edge research and development, Ono aims to provide effective and safe medications to improve the quality of patients' lives globally.
Ono Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Ono Pharmaceutical Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, and Eisai Co Ltd.
Ono Pharmaceutical Co Ltd is a renowned pharmaceutical company based in Japan. Established in 1712, the company has a long-standing history in the healthcare industry. Ono Pharma focuses on the research, development, and manufacturing of innovative drugs and therapeutic solutions. With a strong commitment to improving global health, the company has made significant contributions to the field of oncology, immunology, and central nervous system disorders. Ono Pharma has collaborated with various international partners to expand its reach and enhance its product portfolio. Continuously striving for excellence, Ono Pharmaceutical Co Ltd has emerged as a trusted name in the pharmaceutical sector with its dedication to advancing medical science and improving patient outcomes.
Ono Pharmaceutical Co Ltd has achieved several significant milestones. Notably, they received approval for Opdivo, an anti-cancer medication, from the U.S. Food and Drug Administration (FDA) in 2014. This approval marked a major breakthrough in cancer treatment, leading to increased survival rates for patients with lung cancer, melanoma, and renal cell carcinoma. Additionally, Ono Pharmaceutical Co Ltd successfully expanded Opdivo's indications for other cancers such as bladder cancer and liver cancer in subsequent years. Furthermore, the company has formed strategic partnerships with international pharmaceutical companies, further strengthening its position in the global market.
Ono Pharmaceutical Co Ltd is primarily present in Japan.
Ono Pharmaceutical Co Ltd represents values of innovation, integrity, and commitment to improving human health. Their corporate philosophy focuses on putting patients first and striving for excellence in research and development. Ono Pharmaceutical aims to contribute to society by developing innovative medicines and therapeutic solutions. With a strong emphasis on compliance and ethical standards, the company actively engages in collaborations and partnerships to accelerate the discovery and development of novel therapies. Through their dedication to advancing healthcare and delivering value to stakeholders, Ono Pharmaceutical Co Ltd has established itself as a leading player in the pharmaceutical industry.
Analysts currently set an average price target of 2,128.09 JPY for the Ono Pharmaceutical Co stock (median: 1,989.00 JPY), implying -13.2 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Ono Pharmaceutical Co stock: 1 recommend buying, 12 holding and 7 selling.
Converted at the current exchange rate, the Ono Pharmaceutical Co share trades at 14.23 EUR (2,505.00 JPY).
The Ono Pharmaceutical Co share (4528.T) is listed on 4 stock exchanges, including: Tokio (JPX) (4528.T), Frankfurt (ON4.F), München (ON4.MU).
Ono Pharmaceutical Co. Ltd is a Japanese pharmaceutical company specializing in the development and distribution of innovative medications for over 70 years. It is headquartered in Osaka and focuses on multiple areas including oncology, immunology, neurology, and infectious diseases. In the field of oncology, Ono has established a leading position in the Asian market and offers a range of innovative treatment options for various types of cancer such as breast, lung, and prostate cancer. Some of their well-known products include Opdivo, an immunotherapy for treating different tumors, and Kyprolis, a medication for multiple myeloma. In the field of immunology, Ono focuses on developing treatments for autoimmune diseases and inflammation. This includes products such as Nivolumab for treating melanoma and renal cancer, Ozanimod for multiple sclerosis, and Etrolizumab for Crohn's disease and ulcerative colitis. Their neurology department encompasses medications for treating conditions like schizophrenia, depression, Parkinson's, and epilepsy. Well-known products in this area include antipsychotics like Olanzapine and Aripiprazole, as well as antiepileptics like Rufinamide and Gabapentin. Ono is also actively involved in developing therapies to combat infectious diseases. Some products in this area include Symbicort for asthma treatment and Dulera, an inhalable corticosteroid for seasonal and perennial allergic rhinitis. Ono's business model is based on continuous research and development of innovative medications that meet the needs of patients and doctors. The company continuously invests in research and development to meet the demands of the fast-paced pharmaceutical industry. Strategic partnerships with other pharmaceutical companies and university research departments also aim to expand their product range. In addition to product development, Ono also invests in improving its manufacturing processes and distribution channels. The company closely collaborates with distribution partners to market its products in Japan and internationally. Ono operates several subsidiary companies, including Ono Pharma USA Inc. and Ono Pharma UK Ltd., to distribute its products worldwide. The company aims to achieve a global reach and constantly expands its international network through partnerships with other companies and academic institutions. Overall, Ono Pharmaceutical Co. Ltd is a leading pharmaceutical company specializing in the development and marketing of innovative medications in various fields. With a strong presence in the Asian market and a growing international reach, Ono remains an important player in the pharmaceutical industry.
The revenue of Ono Pharmaceutical Co is 515.79 B JPY. This figure is based on current financial data and reflects the company's business performance.
The profit of Ono Pharmaceutical Co is 69.77 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Ono Pharmaceutical Co is currently 16.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ono Pharmaceutical Co stock.
The price-to-sales ratio (P/S) of Ono Pharmaceutical Co is currently 2.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ono Pharmaceutical Co stock.
The Eulerpool Quality Score for Ono Pharmaceutical Co is 4/10.
The ISIN of Ono Pharmaceutical Co is JP3197600004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ono Pharmaceutical Co is 859650. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ono Pharmaceutical Co is 4528.T. The ticker symbol is used to trade Ono Pharmaceutical Co shares on the stock exchange.
Ono Pharmaceutical Co stock
Ono Pharmaceutical Co Peer Group
Ono Pharmaceutical Co Ticker
Ono Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Ono Pharmaceutical Co
Our stock analysis for Ono Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.